Biotech Values

[dewophile]

clevudine moa
the company also believes clevudine is unique in having better activity in reducing cccDNA, which could in theory contribute to better sustained response off therapy

fwiw if SVR does become a goal of future HBV therapy combinations with INF make sense (note inf is rarely used in HBV due to toxicity and modest efficacy, but it does have an sAg conversion rate and sustained response that is still better than nukes)